Literature DB >> 11490354

Adenosine analogue reduces spinal cord reperfusion injury in a time-dependent fashion.

D C Cassada1, C G Tribble, A K Kaza, S M Fiser, S M Long, J Linden, J M Rieger, I L Kron, J A Kern.   

Abstract

BACKGROUND: We hypothesized that inflammation during spinal cord reperfusion worsens ischemic injury. ATL-146e, an adenosine A(2A) agonist with known anti-inflammatory properties, was used to test this hypothesis at varied intervals to determine the time course of reperfusion injury.
METHODS: Forty rabbits underwent cross-clamping of the infrarenal aorta for 45 minutes. One group (n = 14 animals) received 0.06 microg/kg/min systemic ATL-146e over 3 hours, beginning after 30 minutes of ischemic time. A second group (n = 6 animals) received ATL-146e over 1.5 hours. A third group (n = 3 animals) received ATL-146e over 1 hour, and a fourth group (n = 17 animals) received saline solution. All animals were assessed at 48 hours for hind limb motor function (Tarlov scale, 0-5).
RESULTS: Animals that received ATL-146e for 3 hours (Tarlov score, 4.3 +/- 0.22; P <.001) or 1.5 hours (Tarlov score, 2.7 +/- 0.6; P <.05) had improved neurologic outcomes compared with rabbits that received saline solution (Tarlov score, 0.6 +/- 0.29). Animals that received ATL-146e for 1 hour (Tarlov score, 0.7 +/- 0.8) were not significantly different from those animals that received saline solution.
CONCLUSIONS: Systemic ATL-146e, given during reperfusion, results in time-dependent improvement in spinal cord function after ischemia. This implies that the mechanism of spinal reperfusion injury includes leukocyte-mediated inflammation at a critical post-ischemic time interval.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11490354     DOI: 10.1067/msy.2001.115838

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  2 in total

1.  Early adenosine receptor activation ameliorates spinal cord reperfusion injury.

Authors:  T Brett Reece; Curtis G Tribble; David O Okonkwo; Jonathon D Davis; Thomas S Maxey; Leo M Gazoni; Joel Linden; Irving L Kron; John A Kern
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2008-04       Impact factor: 2.160

Review 2.  Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells.

Authors:  M Sitkovsky; D Lukashev; S Deaglio; K Dwyer; S C Robson; A Ohta
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.